Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know
- Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis
- Mizuho Securities Recommends Buy for Apogee Therapeutics Due to Promising APG777 Efficacy in Th2 Inflammatory Diseases
- Apogee Therapeutics initiated with an Outperform at Mizuho